General Catalyst
US multi-stage investor with $43bn+ AUM and a London office; backed Multiverse, Doccla and PhysicsX
- Venture capital
- Type
- Venture capital
- Based in
- Outside the UK
- Stages
- Pre-seed, Seed, Series A, Series B+, Growth
- Sector focus
- AI & Data, Healthtech, SaaS & B2B, Fintech, Deeptech, Edtech
- Fund size
- $43B+ assets under management (as of 30 Sep 2025)
- Founded
- 2000
- Website
- generalcatalyst.com
General Catalyst is a US investment firm with more than $43 billion under management and a portfolio of over 900 companies. It invests from company creation and seed through to growth rounds, with particular depth in AI, healthcare, defence and financial services, and runs adjacent platforms including GC Wealth and the General Catalyst Institute. The firm is led from San Francisco with six offices worldwide, including London. In the UK it co-led Multiverse's $220 million Series D in 2022, participated in Doccla's Series B in 2024 and joined PhysicsX's $300 million Series C in 2026, generally entering at Series B or later.
Team
- Hemant Taneja, CEO
- Jeannette zu Fürstenberg, President & Managing Director
- Chris Bischoff, COO GC Capital & Managing Director (London)
- Ken Chenault, Chairman & Managing Director
Portfolio in the directory
← All investors · Is this your organisation? Request an update
More investors in the directory
Speedinvest
Vienna-based European seed VC with a London office; led seeds for Breathe and Gyre Energy
SoftBank Vision Fund 2
SoftBank's London-managed growth fund; led rounds for CMR Surgical, Gousto and OakNorth
Partech
Paris-based global VC founded in 1982; co-led Prolific's Series A and Track Titan's seed
Lightspeed Venture Partners
Silicon Valley multi-stage VC with a European team; backed ElevenLabs, Granola and Multiverse
Lakestar
Zurich-based European multi-stage VC; led rounds for Accurx, Doccla and Fyxer
Innovate UK
UK government innovation agency awarding non-dilutive grants; backed SECQAI, Sentai and Papcup
Subscribe to Newsletter
UK startup news, founder stories and funding insight, straight to your inbox every week. Free.